A review on characteristics and analytical methods of atovaquone – a potent antimalarial agent by Sharma, Sanyam et al.
31 
 
 
*For Correspondence: kamya.goyal7@gmail.com 
©2020 The authors 
This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, 
distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or 
the publishers. (https://creativecommons.org/licenses/by-nc/4.0/) 
 
Journal of Applied Pharmaceutical Research  
Volume 8, Issue 3, Year of Publication 2020, Page 31 – 37 
DOI: 10.18231/j.joapr.2020.v.8.i.3.31.37 
 
Review Article 
JOURNAL OF APPLIED PHARMACEUTICAL RESEARCH | JOAPR 
www.japtronline.com                ISSN: 2348 – 0335 
 
 A REVIEW ON CHARACTERISTICS AND ANALYTICAL METHODS 
OF ATOVAQUONE – A POTENT ANTIMALARIAL AGENT 
Sanyam Sharma, Rahul Sharma, Arti Devi, Shammy Jindal, Kamya Goyal* 
 
Article Information  ABSTRACT 
Received: 19th November 2019  Drugs used in the treatment of malaria that is caused by various plasmosium species i.e. P. 
falciparum, P. vivax are most irresistible disease throughout the world. The different medications 
are utilized in the treatment of malaria incorporated the Aryl aminoalcohol mixes: Quinine, 
Quinidine, Chloroquine, Mefloquine; Antifolate compound: Pyrimethamine, Proguanil, 
Chlorproguanil, Trimethoprim and Atovaquone. Atovaquone is most effective drug utilized in 
the treatment of malaria. It must be given in single or in mixture with different antimalarials. An 
enormous number of methodologies including High Performance Liquid chromatography 
(HPLC), UV–Visible spectroscopy and Liquid Chromatography-Mass Spectroscopy (LC-MS) 
are utilized for the determination of atovaquone. Various analytical methods are used for the 
analysis of pharmaceutical products and these methods were validated according to ICH 
guidelines (Q1A R2). Thus, this technique can be safely used for the standard quality control 
analysis of atovaquone. 
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INTRODUCTION 
Malaria is a mosquito-borne infection brought about by 
plasmodium parasites. Patients with malaria generally 
experiences flu-like manifestations. In serious cases, the ailment 
can advance to neurological disturbances, unconsciousness and 
death. Symptoms generally start ten to fifteen days after nabbed 
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by a tainted mosquito. Malaria is endemic in tropical and 
subtropical localities and cause approximately one million death 
every year [1]. 
Malaria parasites have a place with the variety Plasmodium 
(Phylum apicomplexa). In people, malaria is brought about by P. 
falciparum, P. malariae, P. ovale, P. vivax and P. knowlesi. 
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Among those tainted, P. falciparum is the most well-known 
species distinguished (~75%) trailed by P. vivax (~20%). 
Although P. falciparum customarily represents most of deaths, 
late proof proposes that P. vivax malaria is related with 
conceivably perilous conditions about as frequently likewise 
with a finding of P. falciparum infection. P. vivax relatively is 
increasingly basic outside Africa. There have been filed human 
pollutions with a couple of sorts of plasmodium from higher 
gorillas; regardless, beside P. knowlesi which is a zoonotic 
animal varieties that causes malaria in macaques [2]. Just female 
mosquitoes feed on blood, male mosquitoes feed on plant nectar 
and don't transmit the sickness. Females of the mosquito class 
anopheles went to encourage around evening time. They as a 
rule start scanning for a supper at nightfall and proceed during 
that time until they succeed.  Malaria parasites can likewise be 
transmitted by blood transfusions, in spite of the fact that this is 
uncommon [1]. 
 
In 2018, According to WHO survey report the mostly malaria 
cases were in Africa (93%), East Asia Region (3.4%), Eastern 
Mediterranean Region (2.4%). The P. falciparum found mostly 
spread malaria in African Region (99.7%) of reported malaria 
cases in 2018, similarly as in the WHO South East Asia Region 
(a large portion of), the WHO Eastern Mediterranean Region 
(71%) and the WHO Weastern Pacific Region (65%) [3, 4]. 
 
Between 2015 and 2018, just 31 nations, where malaria is as yet 
endemic, diminished case frequency fundamentally and were on 
track to decrease occurrence by 40% or more by 2020. Without 
quickened change, the Global specialized procedure for malaria 
2016–2030 (GTS) achievements for horribleness in 2025 and 
2030 won't be accomplished [4]. 
 
Now a days, resistance to antimalarials are the topic of 
discussion. The outgrowth of chloroquine resistance has been 
accomplice with a theatrical increase in malaria in endemic 
regions [6,7]. Chloroquine resitant P. falciparum malaria 
occurred from chromosomal mutation. In chloroquine 
obstruction, there is change in the chloroquine collection in the 
digestive vacule in intraerythrocytic tropozoite [8]. In 
chloroquine resistance, there is multiple mutation of PfCRT, a 
protein that behaves like transporter in parasite’s digestive 
vacuole membrane [3, 4]. Huge chloroquine resistance for both 
P. vivax and P. falciparum. Among both, P. vivax was more fetal 
to young children. There is great need to study about resistance 
for chloroquine and its further treatment [9, 10]. 
 
The analytical techniques are used for the qualitative and 
quantitative analysis of drugs in bulk as well as pharmaceutical 
formulations. The techniques are very much useful in past and 
present scenario. The popular analytical techniques are UV-
Visible spectroscopy, High Performance Liquid 
Chromatography (HPLC), Mass spectrometry, Hyphenated 
techniques like GC-MS, LC-MS, LC-NMR etc. In this review, 
we have discussed some analytical techniques of atovaquone in 
bulk as well as formulations 
 
Malaria life cycle 
Sporozoites from the mosquito salivary glands quickly enter the 
circulation after a nibble and limit through openresponse 
occasions in hepatocytes, where they change, grows and form 
into tissue schizonts. This fundamental asymptomatic tissue 
(pre-erythrocytic or exoerythrocytic) period of infection 
continues for 5 to 15 days, relies on the plasmodium species. 
Tissue schizonts then split each discharge thousands merozoites 
that enter the circulation, attack erythrocytes and start the 
erythrocytic cycle.  
 
At the point when the tissue schizonts burst in P. falciparum and 
P. malariae infections, no types of the parasite stay in the liver. 
Be that as it may, in P. vivax and P. ovale diseases, tissue 
parasites (hypnozoites) continue that can deliver backslides of 
erythrocytic contamination months to years after the essential 
assault. When plasmodia enter the erythrocytic cycle, they can't 
reinvade the liver, along these lines, there is no tissue phase of 
contamination for jungle fever shrunk by transfusion. In 
erythrocytes, most parasites experience agamic improvement 
from youthful ring structures to trophozoites lastly to develop 
schizonts. Schizont-containing erythrocytes burst, each 
discharging 6 to 32 merozoites relying upon the plasmodium 
species. It is this procedure that produces febrile clinical 
assaults. The merozoites attack more erythrocytes to proceed 
with the cycle, which continues till the very end of the host or 
adjustment by drugs or procured halfway insusceptibility. The 
periodicity of parasitemia and febrile clinical signs relies upon 
the planning of schizogony of an age of erythrocytic parasites. 
For P. falciparum, P. vivax and P. ovale, it takes around 48 hours 
to finish this procedure; for P. malariae, around 72 hours is 
required [11-14]. 
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Figure 1: Life cycle of malaria [15] 
Antimalarial drugs are used for treating malaria. The aim of 
treatment is to prevent mortality from severe malaria illness and 
to cure fever, chills, sweating like symptoms that are produced 
during plasmodia release into blood stream [15-16]. All the 
antimalarials have their different mode of action for malaria 
disease. Some are active in pre-erythocytic stage and some are 
active in erythrocytic stage. Some drugs are given for malaria 
prophylaxis [17-18]. The drugs which are active against P. 
falciparum are also active against other species of malaria that 
effects the human beings. The focused strategies goes on 
development of fast acting blood schizontocidal antimalarial 
drugs and resistant P. falciparum antimalarials in all over the 
world [19-20]. 
 
Table 1: Various classes of antimalarial drugs [16]. 
Class Drugs 
4-Amino quinolines Chloroquinine, 
Amodiaquine, Piperaquine 
Quinoline methanol Mefloquine 
Cinchona Alkaloid Quinine, Quinidine 
Biguanides Proguanil, Chloroproguanil 
Diamino Pyrimidine Pyrimethamine 
8-Amino quinoline Primaquine, Bulaquine 
Sulfonamide and Sulfones Sulfadoxine, Dapsone 
Tetracycline Doxycycline 
Sesquiterpene lactones Artesunate, Artemether, 
Arteether 
Amino alcohols Halofantrine, Lumefantrine 
Mannich base Pyronaridine 
Napthaquinone Atovaquone 
 
Atovaquone is a hydroxy napthaquinone or an analogue of 
ubiquinone which is highly lipophillic in nature and used for 
treatment and prevention of chloroquine–resistant P. falciparum 
in combination with proguanil. Atovaquine is a potent anti-
malarial drug and plays vital role in disease management of 
malaria because of drug resistance, intolerable side effects of 
other anti-malarials [21-35]. 
 
 
 
 
 
 
Figure 2: Chemical structure of atovaquone 
IUPAC name 2-hydroxy-3-{(1R,4R)-4-(4-
chlorophenyl)cyclohexyl}-1,4-
dihydronapthalene-1,4-dione 
Molecular formula C22H19ClO3 
Solubility Ethanol, Methanol, slightly soluble in 
water 
LogP 5.9 
Half life 2.2 -3.2 days 
Molecular weight 366.8 g/mol 
Melting point 216–219 ºC 
Mechanism of action 
Atovaquone is a competitive inhibitor of ubiquinol. It inhibits 
mitochondrial electron transport chain at the bc1 complex that 
leads to loss of mitochondrial function.Atovaquone hinder 
mitochondrial ETC (Electron Transport Chain) particularly at 
cytochrome  bc1 complex [21,34]. During intra-erythrocytic 
phase of infection, a key job of the parasite in mitochondria is to 
give orotate for pyrimidine through the action of dihydro-orotate 
dehydrogenase (DHODH). Inhibition of bc1 complex by 
atovaquone impacts on the concentraton of metabolites in the 
pyrimidine biosynthesis pathway [28, 32, 36, 37]. 
 
Absorption: The bioavailability of atovaquone is low and is 
profoundly subject to formulation and diet. Bioavailability of the 
suspension expands two-crease when administered with suppers. 
When administered with food, bioavailability is around 47%. 
Without food, the bioavailability is 23% [33, 34, 26]. 
 
Volume of distribution: 0.60± 0.17 L/kg [24, 34]. 
Protein binding: 99% plasma proteins [24, 34]. 
 
H
Cl
H
O
O
HO
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Excretion: The half-life of atovaquone is long becouse of 
enterohepatic cycling and fecal disposal. There was no excretion 
of atovaquine via urine (0.6%) [24]. 
 
UV methods for Atovaquone 
Varsha HC developed an extremely basic and selective UV-
Visible spectroscopic method and validated for the estimation of 
Atovaquone in pure form and the nanosuspension. The 
instrument used for spectrophotometric observations was Varian 
Cary C50. Atovaquone was assessed to be at 494 nm in pH 8 
(Phosphate Buffer and IPA in the ratio of 60:40 v/v). The 
linearity was found between the concentration ranges of 20-140 
µg/ml. The developed method was then validated as per ICH 
guidelines [38]. 
 
Srujani C et al., developed a method for atovaquone by using 
hydrotropic solubilization technique. Hydrotropic solubilization 
technique is utilized for the inadequately water-soluble drugs. 
Piperazine, urea, salicylate, sodium benzoate etc. are used as 
hydrotropic solvents in their different concentrations. The 
Shimadzu UV-1800 spectrophotometer with UV-probe software 
was used for the whole work process. 1M piperazine was used 
for enhancing water solubility of atovaquone. Wavelength is 
assessed to be 274 nm. Linearity was found in the range of 4-20 
µg/ml. The mean percent label claim of tablet formulation of 
atovaquone was found to be 98.75%. The proposed method was 
validated as per ICH guidelines [39]. 
 
Kalpesh NP et al., developed a simple and precised method for 
the estimation of atovaquone in bulk and tablet formulations. 
Wavelength was assessed to be 251 nm using methanol as 
solvent. The linearity range was within 1-10 µg/ml. The 
validation of method was done as per ICH guidelines and the 
method was used for investigation of atovaquone marketed 
formulation. The label claim ± standard deviation was founded 
99.14±1.14%. This methodic strategy was applied in routine 
analysis in bulk drugs as well as formulation of Atovaquone 
[40]. 
 
HPLC methods for Atovaquone 
Lakshmana Rao A et al., developed a simple and precise RP-
HPLC method for the simultaneous estimation of Proguanil and 
Atovaquone in pharmaceutical dosage form. Chromatographic 
separation was carried out by using kromasil C18 column 
(150mm × 4.6mm, 5µm) utilizing mobile phase 0.1% 
OPA:ACN in ratio 50:50 having 1ml/min flow rate with 287nm 
UV detection. The retention time were 2.15 and 2.48 min for k 
respectively. The developed method was validated as per ICH 
guidelines. Linearity of the method was good over the 
concentration range 25-150 µg/ml for proguanil and 6.25-375 
µg/ml for atovaquone. The percent mean recovery of proguanil 
and atovaquone was with the range of 98.86 – 99.97%. This 
method is suitable for the routine analysis of atovaquone in bulk 
as well as tablet formulation [41]. 
 
Naazneen S. and Sridevi A. developed a precised and rapid RP-
HPLC method for the estimation of atovaquone and proguanil in 
tablet formulations. The method was carried out by using 
gradient HPLC on C18 column (250mm × 4.6 mm, 5µ) and 
mobile phase comprised of 10 mM ammonium formate, pH 3.5 
and 90:10 v/v acetonitrile-methanol in ratio of 30:70 v/v. The 
flow rate was 0.9 ml/min and effluent were monitored at 254 nm. 
The retention time of atovaquone and proguanil were 7.3 and 3.8 
min respectively. The method was validated as per ICH 
guidelines. Linearity was in the range of 2.5 µg/ml- 20 µg/ml for 
proguanil and 6.25 µg/ml to 50 µg/ml for atovaquone. The 
percent recoveries of both drugs were from 98.38-101.09% for 
proguanil and 98.62-100.99%. This method was introduced for 
regular analysis and also applied for forced degradation studies 
of tablet formulations [42]. 
 
Viplava K and Haritha PV developed a simple and precise HPLC 
method for the determination of atovaquone in bulk drugs. 
Atovaquone was found to be degraded under different set of 
conditions as followed according to ICH guidelines and 
degradants so formed along with atovaquone were separated 
using Thermo Hypersil BDS C18, 250mm×4.6mm×5µm 
columns utilizing Buffer:Acetonitrile (20:80) as mobile phase. 
The flow rate was 1.5 ml/min with wavelength of 283 nm. The 
retention time was seen as 4.9 min. The technique was approved 
according to ICH guidelines. The strategy is utilized for the 
examination of atovaquone within the degraded items formed 
under different stress condition [43]. 
 
Hyphenated techniques for atovaquone 
Sanjay G et al., developed LC-APCI method that described for 
human plasma determination of atovaquone utilizing lapachol as 
internal standard. Plasma extraction of atovaquone was finished 
by single step precipitation technique accomplishing mean 
recovery of 94.17% (CV 8%) without trading off sensitivity 
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(Limit of Quantitation 50.3 ng/mL) or linearity (50.3 ng/mL-
23924.6 ng/mL). Warmed nebulizer in negative various reaction 
observing mode was utilized with transitions m/z 365.2 → m/z 
337.1 and m/z 240.9→ m/z 185.7 for atovaquone and lapachol. 
Chromatographic separation on a Synergi 4 μm Polar-RP 80A 
(150 × 2.0 mm) column using 100 μL of plasma extraction. 
Injection volume was 10 μL analysis run time within minute. 
The created analytical method can be effectively applied to 
pharmacokinetic studies on atovaquone suspension regulated in 
sound volunteers or HIV-infected patients [44]. 
 
Allison BC et al., built up an analytical evaluation of an UPLC-
MS/MS strategy for Atovaquone measurement in plasma. The 
depicted method was adequately delicate for Atovaquone 
evaluation in plasma to help preclinical and clinical 
preliminaries. UPLC-MS/MS is the method used for the analysis 
of atovaquone in plasma samples. Protein precipitate with the 
drug atovaquone and the drug was extracted from 25µL K2-
EDTA. Test solution was the separated on 2.5µm Polar-RP100 
A (100 × 2 mm) column synergi. Atovaquone and its internal 
standard were detected over 1.3 min on an API 4000 mass 
analyzer using an electrospray ionization source. The method 
was validated in accordance with the Food and Drug 
Administration (FDA). From the pharmacokinetic parameters 
the two calibration curves were obtained ranges from 250-5000 
ng/ml and 5000-50000 ng/ml. QC levels for both lower and 
higher concentration ranges prepared at low (750 ng/mL, 12000 
ng/mL), mid (2000 ng/mL, 22500 ng/mL) and high (4250 
ng/mL, 42500 ng/mL) concentrations. The precision and 
accuracy were founded ≤9.1% and≤±9.4%. The dilution, 
stability and matrix effects were studied and results were within 
limits [45]. 
 
CONCLUSION 
In summary, the atovaquone is a novel napthaquinone derivative 
with great clinical applications is widely used in many 
antimalarial formulations. The above described analytical 
methods were regularly used for the quantification and 
identification of atovaquone.  
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